Fact CheckerSign in

NCT07702994Not yet recruiting

Effects of Adapted Snacktivity™ Intervention on Cognition and Self-Care in COPD Patients

Development and Evaluation of a Culturally Adapted Snacktivity™ Intervention to Enhance Cognition and Self-Care in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Source: ClinicalTrials.gov · Last updated 14 Jul 2026

Brief summary (registry, in English)

This clinical trial aims to evaluate whether a culturally adapted Snacktivity™ program can improve cognitive function and self-care abilities in patients with Chronic Obstructive Pulmonary Disease (COPD) in Hong Kong. The main questions it aims to answer are: 1. Does the Snacktivity™ program improve the cognitive function of participants (including both global cognition and targeted subdomains)? 2. Does the program improve participants' self-care abilities? The study consists of three sequential phases: Phase 1 (Co-design workshops): Co-design workshops will be conducted with COPD patients, healthcare professionals (nurses, physical therapists, occupational therapists), and family caregivers to culturally adapt the Snacktivity™ program for Hong Kong COPD patients. Phase 2 (Feasibility Pilot RCT): The adapted program will be tested in a small-scale pilot study to assess its feasibility and short-term clinical effects. Phase 3 (Full-scale RCT): A full-scale randomised controlled trial will be conducted to evaluate the program's efficacy on the primary and secondary outcomes. Participants in the intervention group will be asked to: Participate in the culturally adapted Snacktivity™ program that integrates short, manageable "snacks" of physical activity into daily routines. Wear an activity tracker to monitor physical activity levels. Complete questionnaires at multiple time points assessing cognitive function, self-care abilities, physical activity levels, self-efficacy, exercise capacity, quality of life, anxiety, and depression. Researchers will compare the intervention group to an attention control group (receiving usual care with health education) to see if the Snacktivity™ program leads to greater improvements in these outcomes.

Status (registry)
Not yet recruiting
Study type
Interventional
Enrollment
210 (estimated)
First submitted
30 Jun 2026
Start date
15 Jul 2026
Primary completion date
30 Jun 2028
Lead sponsor
The University of Hong Kong
Diseases
COPD
NCT number
NCT07702994

What you commit to

  • Study type: Interventional
  • Planned participants: 210
  • From 15 Jul 2026 to the primary completion date, 30 Jun 2028
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Inclusion Criteria:
    • Confirmed diagnosis of COPD in accordance with the 2026 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guideline, with a post-bronchodilator ratio of FEV₁/FVC \< 70%;
    • Aged ≥ 60 years;
    • Clinically stable condition;
    • Score at or below the age- and education-adjusted cutoff (16th percentile) on the Hong Kong Montreal Cognitive Assessment (HK-MoCA) 5-minute Protocol, indicating mild cognitive impairment;
    • No exercise contraindications;
    • No active wrist skin conditions that would prevent wearing an activity tracker (Phase 2 \& 3);
    • Willingness to wear an activity tracker during the intervention (Phase 2 \& 3);
    • Possession of a smartphone capable of receiving instant messages (Phase 2 \& 3);
    • Proficiency in Cantonese or Mandarin;
    • Willingness to provide written informed consent and commitment to trial completion.
  • Exclusion Criteria
    • Receipt of oxygen therapy for ≥ 15 hours per day or requirement for mechanical ventilation;
    • History of brain injury or stroke;
    • Presence of severe comorbidities including coronary artery disease, severe hepatic or renal dysfunction;
    • Diagnosis of psychiatric disorders, deafness, severely limited physical mobility, or inability to cooperate with trial interventions;
    • For Phase 2 and Phase 3: Use of medications documented to impact cognitive function.

Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.